Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Stecher

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
JAMA Dermatology|February 26, 2015
Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of PsoriasisKyle M Coleman, Johann E Gudjonsson, Michael Stecher
JAMA Dermatology|October 15, 2015
In ReplyKyle M Coleman, Johann E Gudjonsson, Michael Stecher
Journal of Vascular Surgery|October 5, 2015
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularizationHosam El Sayed, Richard Kerensky, Michael Stecher, et al.
Journal of Drugs in Dermatology : JDD|June 20, 2015
An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric ComorbidityDaniel Carrasco, Michael Stecher, Gigi Claire Lefebvre, et al.
JNCI Cancer Spectrum|October 10, 2023
Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancerHarshabad Singh, Ashley Kang, Lisa Bloudek, et al.
Oncoimmunology|February 7, 2019
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancerRazelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, et al.
The Journal of Investigative Dermatology|November 14, 2017
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized StudyTheodora Kanni, Maria Argyropoulou, Themistoklis Spyridopoulos, et al.
Investigational New Drugs|March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerDavid S Hong, Filip Janku, Aung Naing, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database StudyJohn H Strickler, Ling-I Hsu, Phoebe Wright, et al.
The Lancet. Oncology|January 18, 2017
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyTamas Hickish, Thierry Andre, Lucjan Wyrwicz, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
JAMA Dermatology|February 26, 2015
Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of PsoriasisKyle M Coleman, Johann E Gudjonsson, Michael Stecher
JAMA Dermatology|October 15, 2015
In ReplyKyle M Coleman, Johann E Gudjonsson, Michael Stecher
Journal of Vascular Surgery|October 5, 2015
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularizationHosam El Sayed, Richard Kerensky, Michael Stecher, et al.
Journal of Drugs in Dermatology : JDD|June 20, 2015
An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric ComorbidityDaniel Carrasco, Michael Stecher, Gigi Claire Lefebvre, et al.
JNCI Cancer Spectrum|October 10, 2023
Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancerHarshabad Singh, Ashley Kang, Lisa Bloudek, et al.
Oncoimmunology|February 7, 2019
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancerRazelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, et al.
The Journal of Investigative Dermatology|November 14, 2017
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized StudyTheodora Kanni, Maria Argyropoulou, Themistoklis Spyridopoulos, et al.
Investigational New Drugs|March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerDavid S Hong, Filip Janku, Aung Naing, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database StudyJohn H Strickler, Ling-I Hsu, Phoebe Wright, et al.
The Lancet. Oncology|January 18, 2017
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyTamas Hickish, Thierry Andre, Lucjan Wyrwicz, et al.
Pageof 2